Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1953 2
1954 1
1955 2
1957 5
1958 1
1959 3
1960 5
1961 7
1962 4
1963 4
1964 3
1965 8
1966 8
1967 12
1968 8
1969 13
1970 7
1971 12
1972 7
1973 10
1974 13
1975 15
1976 12
1977 25
1978 22
1979 18
1980 26
1981 25
1982 23
1983 27
1984 21
1985 24
1986 23
1987 44
1988 41
1989 29
1990 47
1991 58
1992 69
1993 75
1994 66
1995 70
1996 84
1997 77
1998 66
1999 81
2000 75
2001 103
2002 97
2003 91
2004 91
2005 83
2006 75
2007 94
2008 84
2009 85
2010 103
2011 121
2012 111
2013 152
2014 158
2015 172
2016 171
2017 193
2018 207
2019 226
2020 284
2021 153
Text availability
Article attribute
Article type
Publication date

Search Results

3,854 results
Results by year
Filters applied: . Clear all
Page 1
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. Mirza MR, et al. Among authors: moore kn. Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32569725 Review.
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Palma DA, et al. Among authors: moore k. Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982687 Clinical Trial.
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Coleman RL, et al. Among authors: moore kn. N Engl J Med. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562800 Free PMC article. Clinical Trial.
Guidelines on the management of ascites in cirrhosis.
Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Aithal GP, et al. Among authors: moore k. Gut. 2021 Jan;70(1):9-29. doi: 10.1136/gutjnl-2020-321790. Epub 2020 Oct 16. Gut. 2021. PMID: 33067334 Free PMC article.
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. Tew WP, et al. Among authors: moore kn. J Clin Oncol. 2020 Oct 20;38(30):3468-3493. doi: 10.1200/JCO.20.01924. Epub 2020 Aug 13. J Clin Oncol. 2020. PMID: 32790492
Myocardial infarction accelerates breast cancer via innate immune reprogramming.
Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, Albers KB, Yamaguchi N, Narke D, Schlegel M, Sharma M, Shanley LC, Barrett TJ, Rahman K, Mezzano V, Fisher EA, Park DS, Newman JD, Quail DF, Nelson ER, Caan BJ, Jones LW, Moore KJ. Koelwyn GJ, et al. Among authors: moore kj. Nat Med. 2020 Sep;26(9):1452-1458. doi: 10.1038/s41591-020-0964-7. Epub 2020 Jul 13. Nat Med. 2020. PMID: 32661390 Free PMC article.
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Palma DA, et al. Among authors: moore k. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2. J Clin Oncol. 2020. PMID: 32484754 Clinical Trial.
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.
Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, López-Picazo JM, Machiels JP, Delord JP, Evans TRJ, Boni V, Calvo E, Topalian SL, Chen T, Soumaoro I, Li B, Gu J, Zwirtes R, Moore KN. Naumann RW, et al. Among authors: moore kn. J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5. J Clin Oncol. 2019. PMID: 31487218 Free PMC article. Clinical Trial.
Olaparib in the treatment of ovarian cancer.
Washington CR, Richardson DL, Moore KN. Washington CR, et al. Among authors: moore kn. Future Oncol. 2019 Oct;15(30):3435-3449. doi: 10.2217/fon-2019-0271. Epub 2019 Sep 3. Future Oncol. 2019. PMID: 31478762 Review.
3,854 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page